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Background: The causes of the underutilization of disease modifying anti-rheumatic drugs (DMARDS) for
rheumatoid arthritis (RA) are not fully known, but may in part, relate to individual patient factors including risk
perception. Our objective was to identify the determinants of risk perception (RP) in RA patients and predictors of
their willingness to take a proposed DMARD (DMARD willingness).
Methods: A cross-sectional mail survey of RA patients in a community rheumatology practice. Patients were
presented a hypothetical decision scenario where they were asked to consider switching DMARDs. They evaluated
how risky the proposed medication was and how likely they would be to take it.
Results: The completed sample included 1009 RA patients. The overall survey response rate was 71%. Patient
characteristics: age 61.6 years (range 18-93), 75% female, minority 6.5%, low or marginal health literacy 8.8%,
depression 15.0%, duration RA 13.1 years (range 0.5 – 68). Regression models demonstrated that health literacy,
independent of low educational achievement or other demographic (including race), was a common predictor of
both RP and DMARD willingness. There was partial mediation of the effects of HL on DMARD willingness through
RP. Depression and happiness had no significant effect on RP or DMARD willingness. RP was influenced by
negative RA disease and treatment experience, while DMARD willingness was affected mainly by perceived
disease control.
Conclusions: Risk aversion may be the result of potentially recognizable and correctable cognitive defect.
Heightened clinician awareness, formal screening for low health literacy or cognitive impairment in high-risk
populations, may identify patients could benefit from additional decision support.
Keywords: Decision-making, Risk perception, Depression, Health disparity, Disease-modifying anti-rheumatic
drugs, Rheumatoid arthritisBackground
The prescription of a DMARD for patients with RA is
considered a standard of effective care [1] and there is
increasing expectation for rheumatologists to objectively
measure RA disease activity and to strive to treat patients
to achieve low disease activity [2,3]. However a recent study
of Medicare managed care enrollees found only 63% re-
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reproduction in any medium, provided the oris not fully known; however DMARD decisions are
complex and require patients to consider important
tradeoffs. DMARDs improve arthritis symptoms and
slow the rate of joint damage, but also carry the risk of
serious infections amongst other possible harms [5,6].
When patients consider medication information they
process the risks affectively as well as cognitively [7]. Dif-
fering responses like confidence or anxiety can influence
willingness to take a medication and adherence [8]. A good
decision is informed, consistent with patient values and
acted on [9]. However, this depends on an individual’s
ability to understand and evaluate options and to makeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Martin et al. BMC Medical Informatics and Decision Making 2013, 13:89 Page 2 of 9
http://www.biomedcentral.com/1472-6947/13/89judgments that are relatively free of bias [10]. There is
evidence that a depressed person's diminished ability to
think, concentrate or indecisiveness may impair ability
to participate in decision-making [11]. Risk assessments
can be biased by emotion in part through increased use
of the affect heuristic in judging risks rather than more
deliberate processing of data [12]. However the specific
effects of depression, happiness, and cognition on risk
perception have been only incompletely studied in med-
ical decisions. In this study we evaluate how patient demo-
graphics, RA disease and treatment related experience,
mood and health literacy influence risk perception and
DMARD willingness.
The integrated model of behavioral prediction (IMBP)
proposes that peoples’ willingness to take a medication
are influenced by their beliefs about the expected out-
comes of therapy, their social network’s support of and
use of the medication (perceived norm), as well their
perceived ability to implement it (self-efficacy) [13]. In
the model, these three factors plus background variables
such as demographics, individual differences, and exposure
to health messages (i.e. decision aids) can be used to predict
patients’ willingness to take a proposed medication. One
would expect if environmental factors do not impede
medication use, a patient with positive treatment expecta-
tions would have greater willingness to take a proposed
medication. We hypothesized that risk perception could
be a unique patient attribute that might be influenced by
background factors as well as modified by varied formats
of a risk presentation in a decision aid.Methods
Design and setting
We conducted a single center, cross-sectional mail survey
of a community rheumatology practice. Prior to any study
interventions the research protocol was reviewed ruled
exempt by the Michigan State University Institutional
Review Board. The study was a randomized, single blind,
factorial experimental design [14]. The sample frame was
created from the practice electronic health record registry
and included patients having received care between
March 1, 2010 and February 28, 2011 and who were billed
under the ICD-9 code 714.0 (RA). 1436 patients were
identified in total. All patients were included in the survey.
In accordance with the research provision of the practice
HIPAA statement, which all patients had received at the
time of care, all patient records were reviewed and the
most recent Health Assessment Questionnaire 2 score
[15] and Clinical Disease Activity Index [16] were extracted
and written on the last page of the questionnaire. To
maintain complete confidentiality the questionnaire was
anonymous. All patients received a 3 contact mail sur-
vey using the methods described by Dillman [17].Patients
The population was men and women with RA treated in
community rheumatology practice.Study measurements
The survey instrument assessed the following patient
variables:Demographics
Age, gender, ethnicity – race, education, and Medicaid
eligibility were recorded. Participants who reported hav-
ing less than a high-school graduation were classified as
having low education. Participants who reported to be of
Hispanic, African, or Native American decent were clas-
sified as having minority status. Medicaid eligibility was
used as an indicator of low-income status.RA and DMARD related experience
RA disease duration, past as well as current DMARD usage
and duration of use were elicited. Patient appraisal of
current RA control was assessed with the item, “How satis-
fied are you with the current control of your rheumatoid
arthritis?” This was formatted as a 5-point Likert scale
anchored with 1 corresponding to “not at all” and 5 as
“completely satisfied”. To identify patients who had ex-
perienced a past DMARD related serious adverse event,
patients were asked, “ Have you ever experienced a side
effect from a DMARD that was serious enough that you
were hospitalized?” We assessed the level of current
DMARD related side effects with the item, “Thinking
about the DMARD you most recently started. Are you
having any side effects from it that bother you now?”
[18]. Finally we evaluated decision regret of their most
recent DMARD choice with the Decision Regret Scale [19].
This is a 5 item index that evaluated the presence of regret
or remorse of a decision made. Post- decision regret has
been found to correlate strongly with satisfaction with
decision and decisional conflict [19].RA disease status
The Health Assessment Questionnaire 2 (HAQ 2) [15], a
validated derivation of the Stanford modified Health
Assessment Questionnaire, which measures functional
impairment, was utilized as an indicator of RA severity.
The Clinical Disease Activity Index (CDAI) is a measure
of RA disease activity that sums a physician derived 28
joint swollen and tender joint count, physician global
assessment of disease activity and patient global assess-
ment of disease activity into a single, continuous, com-
posite measure of RA disease activity that ranges from
0-76 [16]. A score of 0-10 is classified as low, 11-22
moderate, and ≥23 high disease activity.
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Happiness was evaluated with a single 9 point Likert
scale, “Taken all together, how would you say things are
these days?” [20].
Depression
Subjects completed the Patient Health Questionnaire-2
which is a two question screening instrument used to
evaluate depressive symptoms [21]. In a validation sample
population with a prevalence of 7% of major depressive
disorder or 18% any depressive disorder the sensitivity and
specificity were 82.9% and 90.0% respectively to identify
patients with major depressive disorder and 62.3% and
95.4% and respectively to identify patients with any de-
pressive disorder [21].
Health literacy
Health literacy (HL) is a measure of multiple domains
including: reading fluency, ability to locate and use infor-
mation and do simple mathematical tasks. We conceptu-
alized HL as not only a measure useful for classifying
patient’s reading fluency, but also as a broader descrip-
tive indicator of cognitive function including recall and
critical thinking [22]. We used a validated three question
screening index to identify subjects with inadequate or
marginal HL [23]. A score of ≥ 9 on difficulty using
health information has been reported to differentiate
patients with low or marginal HL as measured by the
gold standard Test of Functional Health Literacy in Adults
[24]. To aid readers interpret the findings, we transposed
the health literacy score, such that lower score reflects
lower health literacy.
Risk perception and willingness to take a proposed medication
We presented patients a hypothetical decision scenario
where they were asked to consider switching DMARDs.
Patients were randomized to read 1 of 4 variations of
the format of risk and safety information, which were
derived from an existing DMARD patient decision aid
[25]. The hypothetical scenarios differed in two ways:
SIE risk level and simultaneous presentation or omission
of safety information with the risk statement. We wanted
to evaluate patient perception over a range of risk levels
from what would be considered a relatively low risk of
having a DMARD related SIE to a relatively high risk
which was above the societally determined acceptable
levels. Equal numbers were presented a decision scenario
where the proposed DMARD had a risk of developing a
SIE of 1% or 8%. Similarly, equal numbers were random-
ized to be presented safety-monitoring procedures to
reduce risk of SIE simultaneously (yes or no). In the
regression analyses risk and context were defined as con-
trol variables. An example of the low risk with contextual
safety information condition is depicted in the onlinesupplement. Patients who had a likelihood to take the
proposed medication rating greater than 50% (≥ 5 on a
1-9 scale) were classified as an “intender” and those with
a rating of ≤ 4 were classified as a “non-intender” [13].Analysis
Descriptive analyses were performed to provide informa-
tion on the characteristics of the respondents. Bivariate
relationships were evaluated with Pearson correlation co-
efficients and independent samples t-tests as appropriate.
Differences in categorical variables were evaluated in 2×2
tables calculating odds ratios. We created linear regression
models from the data to identify patient characteristics
that predicted RP and DMARD willingness. Finally we
evaluated the causal hypothesis that RP mediates the
effects of HL on DMARD willingness using methods
described by Baron and Kenny [26,27]. All analysis was
performed with IBM SPSS Statistics version 19.0 [28].Results
1436 patients with RA were surveyed. All participants
were randomized and allocated to intervention. Subjects
were blinded to allocation. Data were analyzed on 1009
respondents. In addition to non-respondents, we learned
that 4 patients had died, 4 had changed address and could
not be reached, and 5 returned the questionnaire without
completion. The overall response rate was 71%. Data from
all study completers were included in the analysis. In
the completed sample all patients had RA. For RP and
DMARD willingness, missing data were 11.2% and 10.0%
respectively. To evaluate if participants with missing values
were systematically different than cases without missing
values [29], we evaluated means of missing values by
estimation-maximization methods. Little’s MCAR test
Chi-Square was P <.01 suggesting that missing values are
not missing completely at random [30]. Review of esti-
mated means of RP and DMARD willingness disclosed as
expected that there were higher rates of missing values
in patients with low health literacy (11.2 vs. 21.8% and
10.0 vs. 18.4% respectively), low education (11.2 vs. 17.7%
and 10.0 vs. 14.5% respectively) and major depression
(11.2 vs. 15.4% and 10.0 vs. 12.6% respectively), but not
in female, low income or minority subjects. As missing
values were not missing completely at random, multiple
imputation was utilized. SPSS performed imputation for
variables with > 10.0% missing values [30].Univariate analysis
Descriptive analysis was performed to provide information
about the general characteristics of the study populations
and is presented in Table 1.
Table 1 Patient characteristics
Demographics
Mean S.D. Range




Less than high school graduation 12.3%
Disease and Treatment Related Experience
RA duration (years) 13.15 11.18 1-68
Number of DMARDs taken 2.45 1.54 0-11
Past or current biologic DMARD use 53.2%
TNF related knowledge 8.39 2.45 1-14
Past hospitalization with SAE 4.0%
Current bother from DMARD side effects 1.52 0.91 0-5
Satisfaction with RA control 3.94 0.97 1-5
Support to take DMARD 13.31 0.50 3-15
Decision regret of current DMARD choice 8.11 23.38 5-25
RA Disease Status
HAQ 2 disability 0.76 0.64 0-3
Clinical disease activity index 11.82 8.41 0-54
Mood and Cognition
Major depression 15.0%
Happiness 6.86 1.77 0-9
Health literacy 13.32 2.51 3-15
Low or marginal health literacy 8.8%
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Correlations of continuous patient characteristics with RP
and DMARD willingness were computed. Risk Perception
was significantly (P < 0.05) positively correlated with age,
HAQ disability, CDAI, bother from current DMARD
side effects, depressive symptoms and post-decision re-
gret RP was significantly (P < 0.05) negatively correlated
with health literacy, TNF knowledge, satisfaction with
current control of RA, happiness, and risk perception.
Willingness to take a proposed medication was signifi-
cantly positively correlated with health literacy, number
of past DMARDS taken, TNF knowledge, and satisfac-
tion with current control of RA, DMARD willingness
was. There were significantly negatively correlated with
age and post-decision regret with DMARD willingness.
Independent sample t-tests disclosed significant (P<0.01)
between group differences in RP in patients who were
depressed, had past experience of a DMARD related
serious adverse event, or were classified as low income
or low educational status. There were no significant
between group differences in RP by recent onset RA
(≤ 3 years), gender, minority status, or past biologic use.We explored differences between intenders and non-
intenders. Overall 31.2% of patients were classified as
non-intenders. They were significantly older, had experi-
ence using fewer DMARDs in the past, had lower health
literacy, less knowledge about TNF inhibiting DMARDs,
had higher levels of post-decision regret related to the
DMARD they had most recently initiated, as well as
and higher perception of medication risk. There was
no difference in happiness, depressive symptoms, HAQ
disability or CDAI. When compared to normal HL pa-
tients, low or marginal HL respondents were significantly
more likely to be non-intenders with an odds ratio (OR)
of 2.39 (95% C.I.1.27 -3.90). Patients with major depres-
sion were no more likely to be non-intenders compared
to non-depressed patients with an OR of 1.17 (95% C.I.
0.79-1.76). Minority and low-income patients were no
more likely to be non-intenders compared to non-minority
or low-income patients with an OR of 1.22 (95% C.I.
0.70-2.15) and OR of 0.76 (95% C.I. 0.54 -1.08) respectively.
Multivariate analysis
The integrative model of behavioral prediction (IMBP),
proposes that a limited number of variables can be iden-
tified to explain a substantial portion of the variance of a
behavior. In the IMBP theorizes that willingness to
perform a target behavior follows from specific beliefs
(rational or irrational) and attitudes a person has about
that behavior [13]. In our survey willingness to take a
proposed DMARD is the target behavior.
We developed linear regression models to identify predic-
tors of RP and DMARD willingness from a broad pool of
variables. These included the survey version control vari-
ables, as well as demographics, RA disease status, RA and
treatment related experience, as well as mood and HL.
Risk Perception and Patient Characteristics: Results
of hierarchical linear regression modeling of predictors
of risk perception are presented in Tables 2 and 3. The
overall model explained 13.5% of the variation of risk
perception which is considered a moderate effect size
[31]. The standardized regression coefficients show after
controlling for risk level, the strongest predictor of RP
was HAQ2 disability, followed by HL, and current or
past experience of DMARD related AE. Age, TNF know-
ledge, happiness and depression, and other demographics
did not significantly add to the predictive power of the
model.
DMARD Willingness and Patient Characteristics: Results
of hierarchical linear regression modeling of predictors of
DMARD willingness are presented in Tables 4 and 5. The
overall model explained 12.7% of the variation of likeli-
hood to take the proposed medication which is considered
a moderate effect size [31]. The collinearity statistics
were within acceptable ranges with all tolerance >0.4
and Variance Inflations factors < 2.2. The standardized
Table 2 Hierarchical regression model summary‐predictors of risk perception
Change statistics
Model Predictors R R2 Adjusted R2 Std. error of the estimate R2 change Sig. F change
1 Survey version control variables .138 .019 .013 2.1759 .019 0.05
2 Demographics .176 .031 .010 2.1794 .012 NS
3 RA disease status .228 .052 .025 2.1626 .021 NS
4 Disease & treatment experience .331 .109 .057 2.1270 .057 0.02
5 Mood .334 .111 .053 2.1315 .002 NS
6 Health Literacy .367 .135 .075 2.1066 .023 0.021
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DMARD willingness were satisfaction with control of
RA and regret related to their previous DMARD choice,
followed by HL, and the level and context of the risk
being presented. Age and other demographic character-
istics, extent of past RA and general DMARD related
experience, happiness and depression did not signifi-
cantly add to the predictive power of the model.
Mediation analysis
In regression analysis reduced HL was significantly as-
sociated with increased risk perception and decreased
DMARD willingness. Though a cross sectional survey
and correlational research methods are not optimal ap-
proaches to evaluate causation, we wanted to evaluate
the degree to which HL’s effect on DMARD willingness
was mediated through risk perception. We conceptual-
ized this with a simplified causal model illustrated in
Figure 1.
First we evaluated the relationship between HL and
DMARD willingness. This demonstrated there was a sig-
nificant effect to be mediated, β = .142 (P< 0.01). Next
we evaluated the effect of the initial variable, HL, with




Survey version ‐safety context .110
Survey version‐risk level .708
HAQ2 Disability .517
Current bother from AE due to most recently initiated DMARD .353
Past DMARD related SAE 1.303
Health literacy -.134




N.S. = Age, female sex, minority, low income, low education, CDAI, duration RA, numβ = - .082 (P<0.01). Finally we demonstrated the mediat-
ing effect of RP on DMARD willingness, the criterion
variable, by simultaneously using RP and HL to predict
DMARD willingness. This revealed a significant rela-
tionship between RP and DMARD willingness, β = - .471
(P<0.01). Once this mediator was taken into account,
the relationship between HL and DMARD willingness
dropped to β = .086 (P<.01). This indicates that RP
partially mediates the relationship between HL and
DMARD willingness.
Discussion
Based on examination of variation of practice patterns
in the Dartmouth Atlas, John Wennberg, M.D. has sug-
gested three general approaches to reduce inappropriate
variation and increase the equity of medical care: in-
crease the amount of effective care, reduce supply sensi-
tive care and increase preference sensitive care [32].
The underuse of DMARDs by patients with RA, is an
example of underutilization of effective care. This may
be explained by healthcare system failures, individual
physician behavior, or in some cases subsets of patients
who are informed but elect not to take medications
recommended in national standards of care. A recentn
rdized coefficients Standardized coefficients t Sig
Std. error Beta
2.290 -.191 NS
.243 .025 .454 NS
.247 .161 2.870 .004
.230 .152 2.252 .025
.146 .146 2.418 .016
.599 .129 2.175 .030
.057 -149 2.368 .018
.190 .055 .718 NS
.045 .065 .957 NS
.391 -.018 -.286 NS
.100 .005 .064 NS
ber of past DMARDs used, past or present biologic use, and TNF knowledge.
Table 4 Hierarchical regression model summary‐predictors of willingness to take proposed DMARD
Change statistics
Model Predictors R R2 Adjusted R2 Std. error of the estimate R2 change Sig. F change
1 Survey version control variables .188 .035 .029 2.5080 .035 .01
2 Demographics .215 .046 .025 2.5135 .011 NS
3 RA disease status .220 .049 .021 2.5183 .002 NS
4 Disease & treatment experience .331 .100 .057 2.4718 .061 0.2
5 Mood .336 .113 .055 2.4752 .003 NS
6 Health Literacy .356 .127 .066 2.4599 .014 .03
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periment of 144 RA patients’ preferences of specific
risks and benefits of treatment found that when com-
pared to white adults with RA, African American RA
patients were more likely to be classified as risk averse
(OR 8.4 [3.1-23.1]) [33]. In general, it is unknown if risk
aversion is an inherent culturally based trait, influenced
by affect, the result of modifiable deficits in knowledge
or arises from potentially correctable cognitive bias [34].
The purpose of our study was to identify, in a large
community cohort of RA patients, if a limited number
of patient characteristics could predict patient risk per-
ception and how this influenced the likelihood to take a
proposed DMARD.
In our analysis, guided by the Integrative Model of
Behavioral Prediction [13], we developed regression models
to identify the determinants of risk perception and predic-
tors of patent's willingness to take the proposed medica-
tion (DMARD willingness). In these we considered
background variables (demographics, socio-economic,
disease and DMARD experience, disease activity and
related disability, support to acquire and administer
DMARDS) and patient beliefs about outcomes of their
current DMARD use (adverse events and satisfaction
with their disease control). The results create a valid
model, which accounts for significant proportion of the




Survey version-safety context -.654 .283
Survey version-risk level -.749 .288
Satisfaction with control of RA -.483 .222
Post-Decision Regret -.125 .053
Depression -.305 .457
Happiness -.020 .117
Health literacy .154 .071
N.S. = Age, female sex, minority, low income, or low education status, HAQ2 Disabil
TNF knowledge, past DMARD related SAE, current Bother From AE d/t most recentlproposed medication. RP and DMARD willingness are
highly correlated, but distinct attributes, which are pre-
dicted by health literacy as well as different aspects of
patients’ DMARD and disease experience. We found
that when risk level and context were controlled for, RP
was influenced by patient functional impairment / RA se-
verity, past experience of a DMARD related serious ad-
verse event, current bother from DMARD related side
effects, as well as HL (see Table 3). In contrast DMARD
willingness, when controlled for risk level and context,
was predicted by satisfaction with RA control, post-
decision regret related to the most recent DMARD choice,
and HL (see Table 5). HL was the only thread that
contributed to both predictive models. Importantly,
depression and happiness did not demonstrate a signifi-
cant effect on either criterion variable. It is notable age,
gender, minority status, low education, low-income
status and TNF knowledge did not contribute to the
prediction of DMARD willingness. Although our data
creates a significant model, it is important to note that
it explains only 12.7% of the variance of willingness to
take a proposed medication. This suggests that other un-
measured variables i.e. doctor patient relationship, more
nuanced measurement of age related cognitive impair-
ment, perceived costs, individual values of benefit com-
pared to risk could significantly add to the predictive
power of the model.take proposed DMARD










ity, CDAI, duration RA, number of past DMARDs, past or current biologic use,
y initiated DMARD, and DMARD support.
Figure 1 Mediation model.
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low educational achievement or other demographics, is
a common predictor of both RP and DMARD willing-
ness. Our meditational analysis suggests that much of
the effect of HL on DMARD willingness was mediated
through RP. The clinical implication is that HL, as an
indicator of cognition, may provide an identifiable pre-
dictor of risk aversion that could be accommodated
through decision support to minimize cognitive bias
[35-37]. In our study population, the 8.8% prevalence of
low or marginal HL, as measured by a simple 3 question
survey, mirrors Shin and colleagues who found utilizing
the ACR Neuropsychological Battery the prevalence of
cognitive impairment in RA patients ranged from 8%
(semantic fluency test) to 29% (visuo-spatial learning/
memory test) [38]. This highlights the frequency with
which rheumatology providers encounter such high-risk
patients, who may not be identified by demographic
characteristics.
When making treatment decisions, patients may use
one or more cognitive strategies. Prospect theory sug-
gests that decision makers carefully weigh multiple attri-
butes of available treatment options before arriving a
rational choice that maximizes benefit [39]. This is theo-
rized to rely on “System 2” which is the mode of think-
ing that directs conscious, deliberate, effortful activities
like choice [40]. Alternatively patients may utilize a
heuristic approach, making simpler more cognitively ef-
ficient decisions using rules of thumb. This is thought
to be directed by “System 1” which is the mode of think-
ing that is unconscious, fast, intuitive and the source of
impressions and feelings at the source of many of our
explicit beliefs [40]. In the setting of patients evaluating
a new DMARD, this might be conceptualized as a ten-
sion between risk as feelings versus risk as analysis [41].
When a patient with reduced HL engages in a conversa-
tion with a physician evaluating medication options, the
constrained time increases cognitive effort. Cognitive
overload could influence their evaluation of risk andwillingness to take the proposed DMARD leading them
to substitute rational deliberation of the facts with the
use of a easier, faster heuristics based on their past RA
and DMARD experiences [40]. Examples might include:
“if I had a side effect before it will happen again” or
accepting the default “I’ll do what the doctor suggests”.
This proposal is consistent with the findings that our
patients’ risk perception was heavily influenced by ex-
perience of greater functional disability as well as past
and present DMARD side effects. In a previous study
we also found that patients’ trust in physician had nearly
seven times the effect on their confidence in a DMARD
decision than any other predictor including numeric
literacy and DMARD knowledge [18]. This offers further
evidence that many patients rely on non-deliberative deci-
sion strategies when choosing a DMARD.
The findings should be interpreted given the limita-
tions of the study. Most notable is that our survey pro-
vided a simulated decision rather than observing an
actual DMARD choice prospectively in the clinic. How-
ever, vignettes have been used in many previous studies
to validly simulate patient and physician decisions [14,42].
In addition if a prospective study design had been utilized,
time and cost would have made it impossible to accrue
1009 patient responses, which provided the statistical
power to evaluate multiple predictor variables each with
small effects. The selection of background and predictor
variables was guided by a widely accepted psychological/
health behavior theory [13] and included an objective
physician collected RA activity measure, the CDAI, plus
patient reported outcomes of disability, appraisal of dis-
ease control as well as DMARD side effects, TNF know-
ledge, and validated screening measures for depression
and HL. To differentiate patients with varied perception
of medication risk, we utilized a simulated decision sce-
nario with high and low risk as well as two different
safety monitoring framing contexts. The response rate
was high at 71%, however as the survey was anonymous,
we were not able to compare the characteristics of
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that there was a differential non-response in subgroups
of patients. Still the findings are important as with 6.5%
minority and 18.6 % Medicaid respondents, our com-
pleted sample was demographically similar to a previous
large random sample of RA patients receiving care in
five geographically dispersed community rheumatology
practices in Michigan [18], thus the results are likely
generalizable to similar populations. Finally a cross-
sectional survey allows the description of the association
of criterion and predictor variables but is not the strongest
design to assert causation between variables.
Conclusion
In our large community-based sample, medication risk
perception seemed to be driven by negative RA disease
and treatment experience, while DMARD willingness was
predicted by perceived disease control. In the comparison
of intenders and non-intenders, non-intenders were sig-
nificantly older, had experience using fewer DMARDs,
had lower health literacy, less knowledge about TNF
inhibiting DMARDs, had higher levels of post-decision
regret related to the DMARD they had most recently
initiated, as well as higher perception of medication risk.
Minority, low-income, and depressed patients were no
more likely to be non-intenders. While clinicians should
be alert to mood disturbance, depression may have less
effect on risk perception and decision-making than pre-
viously proposed [10-12]. While racial disparities with
the under-utilization of DMARDs exist in the US, our
data support a premise that risk aversion could be, in
many cases, the result of a potentially recognizable and
correctable cognitive defect or bias rather than an in-
herent, cultural trait.
When proposing to initiate a new DMARD, clinicians
must be alert for the possibility of cognitive impairment
whether derived from educational, language, age related
decline in information processing or sensory defect that
could effect the patient’s decision making. Time pressures
increase cognitive load, which might justify extending the
time of deliberation beyond the constraints of the office
visit by scheduling a follow up visit, using decision sup-
ports like decision aids, involving family members, or pro-
viding post-visit coaching by other health professionals
[43]. Heightened clinician awareness, formal screening for
low health literacy or cognitive impairment in high-risk
populations, may identify patients could benefit from add-
itional decision support. Further investigation is needed to
evaluate if the use of patient decision aids to extend and
structure deliberation, can increase the use effective care
by the adoption of recommended medications.
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